KLAR Stock Overview
Operates as a pharmaceutical company. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Klaria Pharma Holding AB (publ.) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.40 |
| 52 Week High | SEK 1.15 |
| 52 Week Low | SEK 0.14 |
| Beta | 0.44 |
| 11 Month Change | -35.13% |
| 3 Month Change | -17.63% |
| 1 Year Change | 16.42% |
| 33 Year Change | -93.79% |
| 5 Year Change | -93.27% |
| Change since IPO | -92.06% |
Recent News & Updates
Shareholder Returns
| KLAR | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | -3.4% | 0.9% | -0.2% |
| 1Y | 16.4% | 9.3% | 11.8% |
Return vs Industry: KLAR exceeded the Swedish Pharmaceuticals industry which returned 9.3% over the past year.
Return vs Market: KLAR exceeded the Swedish Market which returned 11.8% over the past year.
Price Volatility
| KLAR volatility | |
|---|---|
| KLAR Average Weekly Movement | 17.9% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in SE Market | 11.2% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: KLAR's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: KLAR's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 5 | Scott Boyer | www.klaria.com |
Klaria Pharma Holding AB (publ.) operates as a pharmaceutical company. It develops Sumatriptan for the treatment of migraine. The company also develops Epinephrine/Adrenaline, which is in Phase I clinical trial for the treatment of acute allergic reaction.
Klaria Pharma Holding AB (publ.) Fundamentals Summary
| KLAR fundamental statistics | |
|---|---|
| Market cap | SEK 57.47m |
| Earnings (TTM) | -SEK 41.64m |
| Revenue (TTM) | n/a |
-7.8x
P/S Ratio-1.4x
P/E RatioIs KLAR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KLAR income statement (TTM) | |
|---|---|
| Revenue | -SEK 7.38m |
| Cost of Revenue | SEK 0 |
| Gross Profit | -SEK 7.38m |
| Other Expenses | SEK 34.26m |
| Earnings | -SEK 41.64m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 21, 2025
| Earnings per share (EPS) | -0.29 |
| Gross Margin | 100.00% |
| Net Profit Margin | 564.53% |
| Debt/Equity Ratio | 0% |
How did KLAR perform over the long term?
See historical performance and comparison